Current therapies for the spinal enthesopathies present in XLH, ARHR2, OPLL, and DISH have no apparent effect on the initiation and progression of enthesopathy and osteoarthritis, and there is very little understanding of factors responsible for initiating and promoting the heterotopic mineralization. The gene discussed is ENPP1; the disease is diffuse idiopathic skeletal hyperostosis.